Nektar Therapeutics to Webcast R&D Day on Nov...( SAN CARLOS Calif. Oct. 27 /- Nekt...)
| HOME >> BIOLOGY >> TECHNOLOGY |
SAN CARLOS, Calif., Oct. 27 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) announced that it will host an R&D Day for investors and analysts at the InterContinental Hotel in New York on Wednesday, November 12, 2008, beginning at 12:00 p.m. Eastern Time. The webcast portion of this event will conclude at approximately 3:30 p.m.
Nektar's R&D Day will consist of a series of presentations and Q&A related to the Company's clinical development programs, key research and development, and industry-leading PEGylation and conjugate chemistry-based drug development platform.
The presentations and Q&A sessions will be accessible via a live audio and slideshow webcast through a link on the Nektar homepage, http://www.nektar.com. The webcast will be available for replay until November 26, 2008.
About Nektar
Nektar Therapeutics is a biopharmaceutical company developing novel
therapeutics based on its PEGylation and conjugate chemistry technology
platforms. Nektar's technology and drug development expertise have enabled
nine approved products for partners, which include leading
biopharmaceutical companies. Nektar is also developing a robust pipeline of
its own high-value therapeutics that addresses unmet medical needs by
leveraging and expanding its technology platforms to improve and enable
molecules.
Stephan Herrera, 415-488-7699
Jennifer Ruddock, 650-631-4954
'/>"/>
| SOURCE Nektar Therapeutics Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
2. Nektar Therapeutics President and CEO Howard W. Robin to Present at Natixis Bleichroeder Second Annual Hidden Gems Conference in New York City
3. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at UBS 2008 Global Life Sciences Conference in New York City
4. Nektar to Announce Financial Results for the Second Quarter of 2008 on Wednesday, August 6, 2008, After Close of U.S.-Based Financial Markets
5. Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit
6. Nektars PEGylation Technology Enables Peptide Mimetic, Highlighted by Data Presented at 45th ERA-EDTA Congress
7. Nektar Receives Patent Covering Pulmonary Targeted Antibiotics
8. Nektar to Announce Q1 2008 Financial Results on Wednesday, May 7, 2008, After Close of U.S.-Based Financial Markets
9. West Concludes Agreement with Nektar
10. Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization
11. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |